Literature DB >> 12439048

Unexpected pleural effusions in 3 pediatric patients treated with STI-571.

Robert Goldsby, Mike Pulsipher, Roberta Adams, Cheryl Coffin, Karen Albritton, Lars Wagner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12439048     DOI： 10.1097/00043426-200211000-00020

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN： 1077-4114            Impact factor:   1.289


× No keyword cloud information.
  6 in total

1.  Imatinib attenuates inflammation and vascular leak in a clinically relevant two-hit model of acute lung injury.

Authors:  Alicia N Rizzo; Saad Sammani; Adilene E Esquinca; Jeffrey R Jacobson; Joe G N Garcia; Eleftheria Letsiou; Steven M Dudek
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-10-02       Impact factor: 5.464

2.  Phase I study of gemcitabine, docetaxel and imatinib in refractory and relapsed solid tumors.

Authors:  Biren Saraiya; Rashmi Chugh; Vassiliki Karantza; Janice Mehnert; Rebecca A Moss; Nelli Savkina; Mark N Stein; Laurence H Baker; Thomas Chenevert; Elizabeth A Poplin
Journal:  Invest New Drugs       Date:  2010-08-10       Impact factor: 3.850

3.  Concurrent male gynecomastia and testicular hydrocele after imatinib mesylate treatment of a gastrointestinal stromal tumor.

Authors:  Hawk Kim; Heung-Moon Chang; Min-Hee Ryu; Tae-Won Kim; Hee-Jung Sohn; So-Eun Kim; Hye-Jin Kang; Sarah Park; Jung-Shin Lee; Yoon-Koo Kang
Journal:  J Korean Med Sci       Date:  2005-06       Impact factor: 2.153

4.  Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.

Authors:  David A Dorr; Rachel Burdon; Dennis P West; Jennifer Lagman; Christina Georgopoulos; Steven M Belknap; June M McKoy; Benjamin Djulbegovic; Beatrice J Edwards; Sigmund A Weitzman; Simone Boyle; Martin S Tallman; Moshe Talpaz; Oliver Sartor; Charles L Bennett
Journal:  Clin Cancer Res       Date:  2009-05-19       Impact factor: 12.531

Review 5.  Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

Review 6.  New targeted molecular therapies for cancer: radiological response in intrathoracic malignancies and cardiopulmonary toxicity: what the radiologist needs to know.

Authors:  Frederico F Souza; Andrew Smith; Cyrillo Araujo; Jyothi Jagannathan; Ciaran Johnston; Kevin O'Regan; Atul Shinagare; Nikhil Ramaiya
Journal:  Cancer Imaging       Date:  2014-07-23       Impact factor: 3.909
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.